ZYVERSA THERAPEUTICS, INC. Income Tax Expense
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Income Tax Expense of -$851.66 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2025-12-31 was $0.00.
- ZYVERSA THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2025-09-30 was -$851.66K.
- ZYVERSA THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2024-12-31 was -$2.96K.
- ZYVERSA THERAPEUTICS, INC. income tax expense (benefit) for the quarter ending 2024-09-30 was $0.00.
- ZYVERSA THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2025 was -$851.66K, a 12726.52% decline from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2024 was $6.75K.
- ZYVERSA THERAPEUTICS, INC. income tax expense (benefit) for fiscal 2023 was -$9.46M.
| Period end | Income Tax Expense (Benefit) 1 month | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$851.66K derived: sum of 2 quarters · filed 2026-03-31 | -$851.66K 10-K · filed 2026-03-31 | ||
| 2025-09-30 | -$851.66K 10-Q · filed 2025-11-19 | -$851.66K 10-Q · filed 2025-11-19 | |||
| 2024-12-31 | -$2.96K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$2.96K derived: sum of 2 quarters · filed 2026-03-31 | $6.75K derived: sum of 3 quarters · filed 2026-03-31 | $6.75K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $9.71K derived: sum of 2 quarters · filed 2025-11-19 | $9.71K 10-Q · filed 2025-11-19 | ||
| 2024-06-30 | $9.71K 10-Q · filed 2025-08-13 | $9.71K 10-Q · filed 2025-08-13 | |||
| 2023-12-31 | -$596.07K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$596.55K derived: sum of 2 quarters · filed 2025-03-27 | -$8.41M derived: sum of 3 quarters · filed 2025-03-27 | -$9.46M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$485.00 10-Q · filed 2024-11-14 | -$7.81M derived: sum of 2 quarters · filed 2024-11-14 | -$8.86M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$7.81M 10-Q · filed 2024-08-09 | -$8.86M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | -$1.05M 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | -$745.05K 10-K · filed 2024-03-25 | ||||
| 2022-09-30 | $47.55K 10-Q · filed 2022-11-14 | $47.55K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |